|
KMID : 1094020180350020035
|
|
Journal of Veterinary Clinics
2018 Volume.35 No. 2 p.35 ~ p.38
|
|
|
Evaluation of ST2 and NT-proBNP as Cardiac Biomarkers in Dogs With Chronic Mitral Valve Disease
|
|
Kim Jung-Kook
Park Jun-Seok
Seo Kyoung-Won
Song Kun-Ho
|
|
|
Abstract
|
|
|
|
Recently assessment of suppression of tumorigenicity 2 (ST2) level has become a useful cardiac biomarker in human medicine. This study compared serum ST2 levels and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels between healthy dogs and dogs with chronic mitral valve disease. Twenty client-owned dogs were investigated. Dogs were divided into normal, asymptomatic, and symptomatic groups. Serum samples were used to measure levels of NT-proBNP and ST2. Samples for NT-proBNP were sent to IDEXX laboratory for analysis while ST2 levels were measured by using a canine interleukin 33 receptor ELISA kit. There was a significant difference in NT-proBNP levels between asymptomatic and symptomatic groups (P < 0.01), and between normal and symptomatic groups (P 〈 0.01). In contrast, ST2 levels were not relatively different between asymptomatic and symptomatic groups (P 〉 0.05). There was no significant difference was observed among all groups in ST2 study. The usefulness of measuring NT-proBNP level as a cardiac biomarker in dogs with chronic mitral valve disease was confirmed, but usefulness of the ST2 level was not observed. Further investigations are needed to evaluate the potential usefulness of ST2 level as a cardiac biomarker in canines.
|
|
|
KEYWORD
|
|
|
ST2, Cardiac Biomarker, CMVD, NT-proBNP, level
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|